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Background: Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care for ﬁrst-line systemic treat-
ment of advanced hepatocellular carcinoma (HCC). Everolimus (E) is a potent inhibitor of mTOR, a pathway frequently
activated in HCC. Preclinical data suggest that the combination S + E has additive effects compared with single-agent S.
Patients and methods: Patients with unresectable or metastatic HCC and Child-Pugh ≤7 liver dysfunction were ran-
domized to receive daily S 800 mg alone or with E 5 mg until progression or unacceptable toxicity. The primary end point
was progression-free survival at 12 weeks (PFS12). The secondary end points included response rate, PFS, time to pro-
gression (TTP), overall survival (OS), duration of disease stabilization (DDS), safety, and quality-of-life (QoL) assessments.
Results: A total of 106 patients were randomized: 46 patients received S and 60 patients received S + E. Ninety-three
patients were assessable for the primary end point and 105 patients for the safety analysis. The PFS12 rate was 70% [95%
conﬁdence interval (CI) 54–83] and 68% (95% CI 53–81) in patients randomized to S and S + E, respectively. The RECIST
(mRECIST) response rate was 0% (23%) in the S arm and 10% (35%) in the S + E arm. Median PFS (6.6 versus 5.7 months),
TTP (7.6 versus 6.3 months), DDS (6.7 versus 6.7 months), and OS (10 versus 12 months) were similar in the S and S + E
arms, respectively. Grade 3/4 adverse events occurred in 72% and 86% of patients in arm S and arm S+ E, respectively.
Patients had similar QoL scores over time, except for a greater worsening in physical well-being and mood in the arm S + E.
Conclusions: No evidence was found that S + E improves the efﬁcacy compared with S alone. Combining 5 mg E with full-
dose S is feasible, but more toxic than S alone. Further testing of this drug combination in molecularly unselected HCCs
appears unwarranted.
ClinicalTrials.gov: NCT01005199.
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introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common ma-
lignancy worldwide, with ∼500 000 new cases per year globally.
Sorafenib, an oral multitargeted tyrosine kinase inhibitor (TKI),
has become the mainstay in the treatment of advanced-stage
HCC based on two randomized, placebo-controlled phase III
trials [1, 2]. Since the approval of sorafenib in HCC, several
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phase III clinical trials have failed to demonstrate superiority of
other agents over sorafenib in the ﬁrst-line setting or impact on
outcome after sorafenib failure [3, 4]. At present, sorafenib
remains the only approved systemic therapy for HCC.
HCC is characterized by complex molecular aberrations
affecting multiple cellular signaling pathways [5, 6]. Therefore,
combining therapies that target different major signaling path-
ways may improve the efﬁcacy of ﬁrst-line treatment over single-
agent targeted therapies. Combination therapies may also
reduce drug resistances following up-regulation of a secondary
pathway in response to single-agent targeted therapies. The
mTOR pathway is activated in a relevant proportion of HCC
[7]. It plays an important role in angiogenesis, cell cycle progres-
sion, and proliferation of liver cancer cells. Everolimus, a rapa-
mycin analog, inhibits the mTOR pathway and blocks tumor
growth in xenograft models of human HCC [8]. The in vivo efﬁ-
cacy of everolimus was potentiated when combined with sorafenib
in orthotopic models of human metastatic HCC, and this combin-
ation strongly inhibited the proliferation of HCC xenografts [8, 9].
In addition, everolimus administered alone and in combination
with sorafenib induced apoptosis and decreased tumor angiogen-
esis. Accordingly, this combination appears to have signiﬁcant
advantages compared with single-agent sorafenib.
methods
This was a multicenter, open-label, randomized phase II trial. The objective
of the trial was to investigate if the combination of sorafenib plus everolimus
(arm S + E) can stop tumor progression, with a sorafenib monotherapy
group (arm S) used to control selection bias.
eligibility criteria
Eligible patients had histo-, cyto-, or radiologically conﬁrmed unresectable
or metastatic HCC that was stage B or C according to the Barcelona Clinic
Liver Cancer (BCLC) staging classiﬁcation [10] and measurable according to
the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. No
prior therapies for HCC were allowed other than liver directed therapies
(chemoembolization was limited to ﬁve treatments), provided that previous-
ly treated lesions remained separate from the target lesions measured for this
trial. Other eligibility criteria included age ≥18 years, WHO performance
status 0–1, Child-Pugh class A or mild Child-Pugh class B (≤7 points) liver
dysfunction, adequate hematologic, hepatic, and renal function indicated by
an absolute neutrophil count ≥1500/µl, platelets ≥75 000/µl, prothrombin
time-international normalized ratio ≤2, serum ALT≤ 5 × upper level of
normal (ULN), and calculated creatinine clearance ≥40 ml/min according to
the Cockcroft-Gault formula.
Exclusion criteria included: known central nerve system metastases, a
history of other primary malignancy within 5 years except for nonmelanoma-
tous skin cancer or adequately treated in situ cervical cancer, prior organ
transplantation, known ﬁbrolamellar HCC or mixed cholangiocarcinoma/
HCC, documented variceal hemorrhage within 3 months before registration,
repeated paracentesis (>1 month), encephalopathy, active infection requiring i.
v. antibiotics, requirement of anticoagulant therapy except for low-dose antic-
oagulants for the maintenance of patency of central venous access or preven-
tion of deep vein thrombosis, current use or anticipated need for drugs that
are known CYP3A4 inhibitors or inducers, prolongation of QTc >500 msec in
screening electrocardiogram (ECG) or family history of long QT syndrome,
and any serious underlying medical condition which could impair the patient
to participate in the trial or to take oral medication. Institutional review
boards at participating centers and health authorities approved the protocol.
The study followed the Declaration of Helsinki and Good Clinical Practice
guidelines. All patients provided written informed consent.
randomization, dose feasibility evaluation,
and treatment plan
Patients were randomly assigned at the ratio 46:60 to receive either sorafenib
(arm S) or sorafenib and everolimus (arm S + E). Randomization was strati-
ﬁed according to ECOG performance status (0 versus 1), extrahepatic spread
(yes versus no), and study site.
Treatment consisted of sorafenib 2 × 400 mg daily alone or with everoli-
mus 5 mg daily. All drugs were given orally as a continuous, uninterrupted
schedule until disease progression, unacceptable toxicity, or withdrawal of
patient consent. The doses of sorafenib and everolimus were based on the
results of a dose-escalation trial in patients with renal cell cancer and normal
liver function [11]. The safety and tolerability of this drug combination in
mildly hepatically impaired patients had not been investigated when this
study protocol was developed.
We evaluated the dose feasibility of everolimus using the ﬁrst nine assess-
able patients of the S + E arm. This evaluation appeared necessary to avoid
an unexpectedly high number of grade 3/4 toxicities with the selected doses
of sorafenib and everolimus, which might have jeopardized the successful
conduct of the trial. Criteria for the dose feasibility evaluation included any
grade 3/4 adverse events (AEs) occurring starting within the ﬁrst 28 days of
treatment or requiring a 2-week interruption of any study drug. If more than
three patients out of the ﬁrst nine patients fulﬁlled the criteria, the dose of
everolimus was to be reduced to 2.5 mg daily for all further patients.
If grade 3/4 AEs occurred, the study drug treatment was interrupted until
toxicities had resolved below grade 2 or discontinued after 3 weeks. For
selected grade 2 AEs (sorafenib: hand–foot skin reaction >7 days, diarrhea,
cardiac events; everolimus: hand–foot skin reaction >7 days, stomatitis, non-
infectious pneumonitis) and reoccurring grade 3 AEs, the doses of sorafenib
and everolimus were reduced by 50%. The best palliative and supportive care
for disease-related symptoms was offered to all patients.
assessments
Tumor response was assessed using the RECIST version 1.1 [12] based on
computerized tomography (CT) or magnetic resonance imaging (MRI)
scans performed at baseline and every 6 weeks until week 18, and every 8
weeks thereafter during treatment administration. Objective responses (com-
plete or partial) were conﬁrmed after a minimum of 4 weeks. Original CT
and MRI scans from baseline, weeks 6 and 12 assessment were reviewed for
tumor response (RECIST), HCC-adapted RECIST criteria (mRECIST [13])
and Choi criteria [14] by two independent radiologists, blinded to the inves-
tigator’s evaluation and the study arms.
A medical history, physical examination, routine blood and urine analysis,
analysis of hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, α-
fetoprotein (AFP), and a pregnancy test for women aged <50 years, were
carried out within 2 weeks of study entry. Clinical visits included assessment
of AEs, serial laboratory testing including AFP, ECG, and physical examina-
tions (once every 2 weeks). HBV DNA or HCV RNA was measured in case of
progressive ALT elevation (≥5 ×ULN or ≥3 × baseline value) in patients with
chronic HBV/HCV infection, respectively. Patients were followed up every 2
months after treatment.
Symptom-related quality of life (QoL) was assessed within 2 weeks of
study entry and every 2 weeks until week 12 with the 18-item subscale of the
Functional Assessment of Cancer Therapy-Hepatobiliary Subscale (FACT-
HS) [15]. Global QoL was assessed with linear analog self-assessment (range
0–100) indicators for physical well-being, mood, coping effort [16], func-
tional performance, and overall treatment burden [17].
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statistics
The primary end point, progression-free survival (PFS) at 12 weeks (PFS12),
was deﬁned as the patient being alive and without radiological evidence of
tumor progression 12 weeks (±7 days) after trial registration. A PFS12 of
≤55% was considered uninteresting, and PFS12 ≥75% was considered prom-
ising, based on the results of the SHARP study [1]. According to Fleming
and A’ Hern [18] with 90% power and a 5% signiﬁcance level, 50 assessable
patients in the arm S + E were required. If more than 33 patients were pro-
gression-free at 12 weeks, the trial therapy was to be considered worthy of
further investigation. The calibration arm S used 38 assessable patients based
on a 95% conﬁdence interval (CI) approach. To take 20% of nonassessable
patients (no trial treatment or insufﬁcient tumor assessments) into account,
the arms were expanded to 60 and 46 patients, respectively.
AEs were graded using the Common Terminology Criteria for Adverse
Event, version 3 (CTCAE v. 3.0) and summarized per patient. Secondary efﬁ-
cacy end points were disease stabilization (DS), deﬁned as either a complete
response, partial response (PR), or stable disease as the best response during
therapy, and time to progression (TTP), PFS, duration of disease stabiliza-
tion (DDS), and overall survival (OS). All patients who received at least one
dose of trial medication were considered as evaluable for safety and second-
ary efﬁcacy (safety population).
Patients’ characteristics and treatment administration were based on the
safety population. Time-to-event end points were analyzed using Kaplan–
Meier methods. No formal comparisons between arms were planned. QoL
was analyzed by a mixed-effect model for repeated measures with treatment
arm as primary covariate.
Statistical analyses were carried out using SAS version 9.2 (SAS Institute,
Inc., Cary, NC) and R version 3.0.1.
results
patient baseline characteristics and disposition
Between December 2009 and February 2013, 106 eligible
patients were randomly assigned to arm S (n = 46) or to arm
S + E (n = 60). One patient in the arm S + E did not receive
study treatment and was excluded from the analysis. All other
patients (n = 105) were assessable for the safety and secondary
end point analyses. Ninety-three patients were assessable for the
primary end point (Figure 1). The median follow-up time was
20 months. Baseline characteristics were balanced between the
treatment arms (Table 1).
treatment administration
Patients received a median daily dose of 800 mg sorafenib in
arm S and 773 mg sorafenib and 5 mg everolimus in arm S + E.
The median duration of sorafenib treatment was 118 and 106
days in arms S and S + E, respectively, and the median duration
of everolimus was 84 days. Sorafenib doses in arm S and arm
S + E were interrupted in 34 (74%) and 49 (83%) patients, re-
spectively, and were reduced in 21 (46%) and 33 (56%) patients,
respectively. Everolimus doses were interrupted in 46 (78%)
patients and were reduced in 24 (41%) patients. At the time of
the analyses, two patients in each arm remained on treatment.
The main reasons for treatment termination were progressive
disease (arm S 64%; arm S + E 51%) and AEs (arm S 21%; arm
S + E 28%).
safety
AEs are summarized in Table 2. The most common AEs were
fatigue, diarrhea, and increase in bilirubin level. Grade 3/4
events occurred in 72% of patients in arm S and 88% in arm
S + E, respectively. No patient experienced liver failure and there
were no treatment-related deaths. Serious adverse events oc-
curred in 14 (30%) patients in arm S and 28 (47%) patients in
arm S + E. No patient had HCV activation in arm S, whereas 2
of 59 (3%) patients had HCV reactivation in arm S + E.
In the interim safety analysis, only one of nine patients in the
arm S + E reported a dose feasibility AE (grade 3 diarrhea);
therefore, it was decided to continue without dose modiﬁcation.
efﬁcacy
Thirty (70%; 95% CI 54% to 83%) patients were progression-
free at 12 weeks in arm S and 34 (68%; 95% CI 53%–81%) in
arm S + E. The median PFS was 6.6 months (95% CI 4.5–8.2) in
arm S and 5.7 months (95% CI 4.5–6.8) in arm S + E. The
median TTP was 7.6 months (95% CI 4.5–8.5) in arm S and 6.3
Randomized (n = 106)
Arm S (n = 46)
Treated (n = 46) Treated (n = 59)
No dose given (n = 1)
No tumor assessment after 11 weeks and
no PD before (n = 5)
No assessment at all (n = 4)
No tumor assessment after 11 weeks
and no PD before (n = 3)
Efficacy population (n = 50)
Safety population (n = 59)
Efficacy population (n = 43)
Safety population (n = 46)
Arm S + E (n = 60)
Figure 1. Consort ﬂow diagram.
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months (95% CI 4.7–9.2) in arm S + E (Figure 2). The median
OS was 10 months (95% CI 7.9–14.3) in arm S and 12 months
(95% CI 9.9–17.9) in arm S + E. No patient in the arm S and six
patients in arm S + E achieved a PR as the best response during
treatment according to RECIST. Within patients in the safety
population having at least one tumor assessment (n = 46 for
arm S and n = 55 for arm S + E), 80% and 84% of them achieved
DS in the arm S and arm S + E, respectively. The median DDS
was 6.7 months in both arms. Three patients in arm S and four
patients in arm S + E received systemic second-line treatment.
correlative studies
Change in tumor size and density, assessed by the independent
reviewer based on CT scans at baseline and 6 and 12 weeks after
treatment initiation according to the mRECIST and Choi criteria,
was available in 45 and 55 patients (6-week assessment) and in
34 and 39 patients (12-week assessment) in arm S and arm S + E,
respectively. Supplementary Table S1, available at Annals of
Oncology online, shows the best objective response during therapy,
as determined by RECIST, mRECIST, and Choi criteria. Best rela-
tive change in lesion size according to mRECIST is shown in sup-
plementary Figure S1, available at Annals of Oncology online.
Sixty-seven (64%) patients had elevated baseline AFP levels,
of which nine patients in arm S and 16 patients in arm S + E
showed a decrease of at least 50% at any stage during treatment
administration.
quality of life
The FACT-HS score was similar over time in both treatment
groups. The odds of having a clinically relevant improvement in
the FACT-HS score (a change of ≥5 points) was higher in
patients in arm S compared with those in arm S + E [odds ratio
with 95% CI 3.2 (1.0–10.9); P = 0.03]. No clinically relevant im-
provement at any time point was reported by 23 patients receiv-
ing S, and by 35 patients receiving S + E, respectively. Patients in
arm S + E reported worse scores for global QoL indicators over
time compared with those in arm S. Signiﬁcant differences in
change from baseline for physical well-being (P = 0.02) and
Table 1. Baseline patient and disease characteristics
Arm
S (N = 46) S + E (N = 59)
n % n %
Median age (years) (range) 65 (39–82) 66 (32–83)
Male 40 87 48 81
ECOG performance status
0 33 72 35 59
1 13 28 24 41
Etiology
Hepatitis B 8 17 10 17
Hepatitis C 13 28 17 29
Alcohol abuse 27 59 25 42
BCLC stage
B 14 30 15 25
C 32 70 44 75
Child-Pugh score
5/6 37 80 50 85
7 9 20 9 15
Portal vein invasion 16 35 16 27
Extrahepatic disease 26 57 32 54
Previous local treatment
TACE 8 17 9 15
TAE – – 3 5
PEI – – 2 3
Radiofrequency ablation 1 2 3 5
Liver resection 2 4 8 14
Radiotherapy – – 2 3
Liver function parameter
Median albumin (g/l) (range) 39 (20–54) 39 (28–55)
Median bilirubin (µmol/l) (range) 17 (5–51) 16 (4–46)
Median INR (range) 1.1 (1.0–1.5) 1.1 (0.9–2.0)
AFP ≥1.5 × ULN 34 74 33 56
Median AFP (ng/ml)a (range) 350 (25–639 116) 350 (10–99 615)
AFP, α-fetoprotein; ECOG, Eastern Cooperative Group; BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization;,TAE, transarterial
embolization; PEI, percutaneous ethanol injection; INR, international normalized ratio; ULN, upper level of normal.
aIn patients with AFP ≥1.5 × ULN.
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mood (P = 0.02) were observed between groups (see supplemen-
tary Figure S2, available at Annals of Oncology online), with
patients in arm S + E reporting a greater worsening until 12
weeks. Of note, baseline scores for mood were worse in arm S
and remained lower over time.
discussion
Despite preclinical models [10–13] and evidence for single-
agent activity of everolimus [19], the combination of sorafenib
plus everolimus was not superior to sorafenib alone in the ﬁrst-
line treatment of HCC patients. Many reasons may have con-
tributed to this ﬁnding.
First, dose adjustments are usually required when combining
two TKIs. In our trial, we explored the full dose of sorafenib and
half of the regular monotherapy dose of everolimus (5 mg
daily). The target doses appeared feasible although many grade
3/4 AEs led to treatment discontinuation. Severe AEs, mainly
hematological toxicity and anorexia, were more frequent in the
S + E arm. Dose-limiting thrombocytopenia was not observed,
contrary to a phase I trial of the same drug combination
in advanced HCC [20]. This may reﬂect differences in the
patient cohorts between trials: we included patients with mild
Child-Pugh class B liver (≤7 points) dysfunction in our trial.
Furthermore, in the phase I trial, the majority of patients were
of Asian origin and had hepatitis B. QoL was similar for
both treatments during the 12 weeks, yet patients receiving
sorafenib plus everolimus reported a greater worsening in
physical well-being and mood than those receiving sorafenib
alone. However, the greater decline in mood for the combined
Table 2. Adverse events according to CTCAE v. 3.0 by patientsa
Arm
S (N = 46) S + E (N = 59)
All grades, n (%) Grade 3, n (%) Grade 4, n (%) All Grades, n (%) Grade 3, n (%) Grade 4, n (%)
Any event 46 (100) 26 (63) 4 (9) 59 (100) 38 (66) 13 (22)
Anemia 1 (2) 1 (2) – 5 (8) 2 (3) 1 (2)
Neutropenia 1 (2) 1 (2) – 5 (8) 5 (8) –
Thrombocytopenia 4 (9) 1 (2) – 15 (25) 10 (17) 1 (2)
Bilirubin 24 (52) 5 (11) – 20 (34) 8 (14) –
ALAT 19 (41) 2 (4) – 26 (44) 4 (7) –
Diarrhea 22 (48) 7 (15) – 38 (64) 12 (20) –
Mucositis 5 (11) 1 (2) – 10 (17) 3 (5) –
Pneumonitis – – – 3 (5) 2 (3) –
Fatigue 34 (74) 11 (24) 1 (2) 39 (66) 14 (24) 3 (5)
Hand–foot syndrome 15 (33) 3 (7) – 17 (29) 5 (8) –
Rash 11 (24) 1 (2) – 16 (27) – –
Anorexia/weight loss 27 (59) – – 33 (56) 11 (19) –
Hemorrhages 4 (9) 1 (2) – 13 (22) 5 (9) 2 (3)
Hyperglycemia – – – 18 (21) 5 (9) 5 (9)
aWorst observed grade per patient per event type.
CTCAE, Common Terminology Criteria for Adverse Events; ALAT, alanine aminotransferase.
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Figure 2. TTP and OS curves.
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treatment has to be interpreted with caution, as patients on
Sorafenib alone had worse baseline scores.
Second, the result for the primary end point of our trial,
PFS12 strictly deﬁned according to radiological criteria, was
higher than anticipated in both arms. Concordantly, TTP was
considerably longer than in previously reported randomized
ﬁrst-line trials [4], even with comparable patient populations.
This might have masked the effects of sorafenib plus everolimus
in this parallel-group randomized phased II trial. While object-
ive response favored the combination treatment, this did not
translate into a prolongation of TTP or OS, as shown previously
in other HCC trials.
Third, a role of mTOR inhibition in the treatment of unse-
lected patients with HCC has not yet been established. The re-
cently reported phase III EVOLVE-1 trial failed to demonstrate
a beneﬁt of everolimus in patients in whom sorafenib treatment
failed [21]. A way forward might be to assess dual mTOR inhib-
ition in HCC. This may overcome the limitation of everolimus,
which only blocks one of the complementary components of
the mTOR pathway (mTORC1) [22].
It remains speculative, whether the everolimus dose used in
our trial is effective enough to control HCC. Sequencing treat-
ments with full doses, as it is standard of care in renal cell car-
cinoma, may be a better approach. In HCC however, only a
minor proportion of patients is available for systemic second-
line treatment. In addition, no evidenced-based systemic treat-
ment has been established after sorafenib progression.
In summary, we found no evidence that adding everolimus to
sorafenib improves clinical efﬁcacy compared with sorafenib alone
in patients with advanced HCC. Further testing of this drug com-
bination in molecularly unselected HCCs seems unwarranted.
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